Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b/2 open-label study of BGB-16673 combination therapy in relapsed or refractory B-cell malignancies
CTR20244676Phase 2Active
- Sponsor
- BeiGene
- Start
- Jan 2025
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of catadegbrutinib in B-cell malignancy, chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by BeiGene. Started Jan 2025; status: active.
02
Drugs
catadegbrutinib
03
Conditions
B-cell malignancychronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on CTR20244676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244676.